Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review
- PMID: 30222709
- PMCID: PMC6208141
- DOI: 10.1097/FPC.0000000000000350
Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review
Abstract
The arylamine N-acetyltransferase (NAT) nomenclature committee assigns functional phenotypes for human arylamine N-acetyltransferase 1 (NAT1) alleles in those instances in which the committee determined a consensus has been achieved in the scientific literature. In the most recent nomenclature update, the committee announced that functional phenotypes for NAT1*10 and NAT1*11 alleles were not provided owing to a lack of consensus. Phenotypic inconsistencies observed among various studies for NAT1*10 and NAT1*11 may be owing to variable allelic expression among different tissues, the limitations of the genotyping assays (which mostly relied on techniques not involving direct DNA sequencing), the differences in recombinant protein expression systems used (bacteria, yeast, and mammalian cell lines) and/or the known inherent instability of human NAT1 protein, which requires very careful handling of native and recombinant cell lysates. Three recent studies provide consistent evidence of the mechanistic basis underlying the functional phenotype of NAT1*10 and NAT1*11 as 'increased-activity' alleles. Some NAT1 variants (e.g. NAT1*14, NAT1*17, and NAT1*22) may be designated as 'decreased-activity' alleles and other NAT1 variants (e.g. NAT1*15 and NAT1*19) may be designated as 'no-activity' alleles compared with the NAT1*4 reference allele. We propose that phenotypic designations as 'rapid' and 'slow' acetylator should be discontinued for NAT1 alleles, although these designations remain very appropriate for NAT2 alleles.
Conflict of interest statement
Conflicts of interest
There are no conflicts of interest.
Figures
References
-
- Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1–17. - PubMed
-
- Hein DW, Grant DM, Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 2000;10:291–2. - PubMed
-
- Boukouvala S, Westwood IM, Butcher NJ, Fakis G. Current trends in N-acetyltransferase research arising from the 2007 International NAT Workshop. Pharmacogenomics 2008;9:765–71. - PubMed
-
- Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993;301:71–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
